(VIANEWS) – Novo Nordisk A/S (NVO), OGE Energy Corporation (OGE), Eli Lilly and Company (LLY) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Novo Nordisk A/S (NVO)
26.6% sales growth and 88.07% return on equity
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Earnings Per Share
As for profitability, Novo Nordisk A/S has a trailing twelve months EPS of $2.71.
PE Ratio
Novo Nordisk A/S has a trailing twelve months price to earnings ratio of 47.75. Meaning, the purchaser of the share is investing $47.75 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 88.07%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Novo Nordisk A/S’s EBITDA is 2.55.
Previous days news about Novo Nordisk A/S(NVO)
- According to Zacks on Tuesday, 26 March, "This field has so far been dominated by Novo Nordisk A/S (NVO Quick QuoteNVO – Free Report) and Eli Lilly and Co. (LLY Quick QuoteLLY – Free Report) ."
2. OGE Energy Corporation (OGE)
24.1% sales growth and 9.34% return on equity
OGE Energy Corp., together with its subsidiaries, operates as an energy and energy services provider that offers physical delivery and related services in the United States. It operates through Electric Company Operations and Natural Gas Midstream segments. The company generates, transmits, distributes, and sells electric energy. In addition, it provides retail electric service to approximately 889,000 customers, which covers a service area of approximately 30,000 square miles in Oklahoma and western Arkansas; and owns and operates coal-fired, natural gas-fired, wind-powered, and solar-powered generating assets. OGE Energy Corp. was founded in 1902 and is headquartered in Oklahoma City, Oklahoma.
Earnings Per Share
As for profitability, OGE Energy Corporation has a trailing twelve months EPS of $2.07.
PE Ratio
OGE Energy Corporation has a trailing twelve months price to earnings ratio of 16.44. Meaning, the purchaser of the share is investing $16.44 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.34%.
Sales Growth
OGE Energy Corporation’s sales growth is 25.2% for the ongoing quarter and 24.1% for the next.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Apr 5, 2024, the estimated forward annual dividend rate is 1.67 and the estimated forward annual dividend yield is 4.97%.
3. Eli Lilly and Company (LLY)
19.2% sales growth and 48.44% return on equity
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Earnings Per Share
As for profitability, Eli Lilly and Company has a trailing twelve months EPS of $5.8.
PE Ratio
Eli Lilly and Company has a trailing twelve months price to earnings ratio of 133.6. Meaning, the purchaser of the share is investing $133.6 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 48.44%.
Moving Average
Eli Lilly and Company’s worth is way higher than its 50-day moving average of $688.83 and way higher than its 200-day moving average of $569.79.
Sales Growth
Eli Lilly and Company’s sales growth is 29.1% for the ongoing quarter and 19.2% for the next.
Volume
Today’s last reported volume for Eli Lilly and Company is 2082320 which is 35.15% below its average volume of 3211410.
4. WEX (WEX)
8.9% sales growth and 15.37% return on equity
WEX Inc. operates a commerce platform in the United States and internationally. The Fleet Solutions segment offers fleet vehicle payment solutions, transaction processing, and information management services. It also provides account and account retention services; authorization and billing inquiries, and account maintenance services; account management; credit and collections services; merchant services; analytics solutions; and ancillary services and tools to fleets to manage expenses and capital requirements. This segment markets its products directly and indirectly to businesses and government agencies with fleets of commercial vehicles; and indirectly through co-branded and private label relationships. The Travel and Corporate Solutions segment provides payment solutions, including embedded payments; and accounts payable automation and spend management solutions. Its products include virtual cards that are used for transactions where no physical card is presented. This segment markets its products directly and indirectly to customers in travel, fintech, insurance, consumer bill pay, and media verticals, as well as businesses and financial institutions. The Health and Employee Benefit Solutions segment offers software-as-a-service (SaaS) platform for consumer directed healthcare benefits and full-service benefit enrollment solutions. Its SaaS platform includes embedded payment solutions and plan administration services for consumer-directed health benefits; COBRA accounts; and benefit enrollment and administration services. This segment also provides custodial and depository services for health savings accounts; and payroll-related benefits. This segment markets its products through third-party administrators, financial institutions, payroll providers, and health plans. The company was formerly known as Wright Express Corporation and changed its name to WEX Inc. in October 2012. WEX Inc. was founded in 1983 and is based in Portland, Maine.
Earnings Per Share
As for profitability, WEX has a trailing twelve months EPS of $6.16.
PE Ratio
WEX has a trailing twelve months price to earnings ratio of 38.31. Meaning, the purchaser of the share is investing $38.31 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.37%.
